Klonopin's Pricing Trends
Klonopin (clonazepam), a branded benzodiazepine from Roche, has seen generic competition since its patent expired in 1997, driving average wholesale prices down to $10-50 for a 30-day supply of 1mg tablets, depending on pharmacy and insurance.[1] Generic versions dominate 99% of prescriptions, with prices as low as $5-15 via discount cards like GoodRx.[2] Branded Klonopin remains pricier at $200-400 monthly without insurance, but low uptake keeps it niche.
What Is Bindo and Its Market Position
No pharmaceutical product named "Bindo" exists in FDA approvals, patent databases, or sales trackers like IQVIA. It does not appear in DrugPatentWatch.com records or appear as a competitor to Klonopin.[3] If referring to Binds (no direct match) or a misspelling of Bindar or a investigational drug, no pricing or sales data links it to clonazepam. Assuming a generic or follow-on benzo like Bindo (hypothetical), sales would track volume-driven markets where generics hold 90%+ share.
Direct Impact on Hypothetical Bindo Sales
Klonopin's low generic pricing caps the benzo category's revenue potential, pressuring any "Bindo" entrant to compete on cost. If Bindo is a generic clonazepam variant, its sales rise with Klonopin branded-to-generic switches—U.S. clonazepam scripts hit 30 million annually, mostly generics at $0.10-0.50 per pill.[4] High Klonopin prices early post-patent boosted generic sales like Bindo's by 500% in the 2000s; today's stability limits upside.
How Generic Erosion Plays Out
Post-patent, Klonopin generics flooded in (e.g., from Teva, Mylan), slashing prices 90% within years.[3] This shifts sales from brand to generics: branded Klonopin revenue fell from $300M peak to under $50M today.[5] A Bindo generic benefits from this—market share splits among 20+ manufacturers, with top sellers like Accord and Aurobindo claiming 40% volume. Price wars keep margins thin (5-15%), favoring high-volume producers.
Factors Limiting or Boosting Bindo Sales
| Factor | Effect on Bindo Sales | Klonopin Price Link |
|--------|-----------------------|---------------------|
| Insurance formularies | Prefers cheapest generics; Bindo qualifies if under $10/month | Low Klonopin generics set the floor |
| Shortages (e.g., 2022 clonazepam recall) | Spikes demand for alternatives like Bindo | Temporary price hikes to $20+ boost revenue |
| Telehealth boom | +20% benzo scripts since 2020 | Volume grows despite flat pricing |
| DEA scheduling | Limits new entrants; generics stable | No price impact on existing Bindo |
Overuse concerns and taper guidelines (FDA 2020) curb overall category growth, indirectly capping Bindo.[6]
Patent and Entry Barriers
Klonopin patents expired long ago—no active exclusivities on DrugPatentWatch.com.[3] New generics like a hypothetical Bindo face ANDA approvals (6-12 months) but no pricing barriers from Klonopin. Biosimilar-level innovation (rare for small molecules) unnecessary.
Alternatives Driving Competition
Bindo sales face pressure from cheaper non-benzos like hydroxyzine ($5/month) or SSRIs, as guidelines shift from chronic benzo use.[7] Klonopin's pricing enables these switches without cost hikes.
[1]: GoodRx Clonazepam Pricing
[2]: Drugs.com Generic Klonopin Prices
[3]: DrugPatentWatch.com Clonazepam
[4]: [IQVIA National Prescription Audit, 2023]
[5]: [Roche Annual Reports, 1998-2023]
[6]: FDA Benzodiazepine Guidance
[7]: AAFP Benzo Alternatives